and Media

News Releases

Portola Pharmaceuticals to Participate in Two Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., Feb. 24, 2020 /PRNewswire/ -- Portola Pharmaceuticals, Inc.® (NASDAQ: PTLA) today announced that the Company will participate in the following conferences in March.

Portola Pharmaceuticals, Inc. Logo (PRNewsfoto/Portola Pharmaceuticals, Inc.®)

  • Cowen 40th Annual Health Care Conference on Tuesday, March 3, 2020, at 10:00 a.m. ET in Boston, MA.

  • Oppenheimer 30th Annual Healthcare Conference on Tuesday, March 17, 2020, at 2:45 p.m. ET in New York, NY.

Both presentations will be webcast live and available for replay in the Investor Relations section of the Portola website at

About Portola Pharmaceuticals, Inc.
Portola Pharmaceuticals is a global, commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics that could significantly advance the fields of thrombosis and other hematologic conditions. The Company's first two commercialized products are Andexxa® [coagulation factor Xa (recombinant), inactivated-zhzo], marketed in Europe as Ondexxya® (andexanet alfa), and Bevyxxa® (betrixaban). The company also is advancing cerdulatinib, a SYK/JAK inhibitor being developed for the treatment of hematologic cancers. Founded in 2003 in South San Francisco, California, Portola has operations in the United States and Europe.

SOURCE Portola Pharmaceuticals, Inc.®

For further information: Investor Contact: Jennifer Zibuda, Portola Pharmaceuticals,; Media Contact: Emily Faucette, Portola Pharmaceuticals,